



FAKULTAS KESEHATAN MASYARAKAT UNIVERSITAS AHMAD DAHLAN

Alamat: Jl. Prof. Dr. Soepomo, Janturan, Warungboto, Umbulharjo, Yogyakarta 55164
Telp. (0274) 563515, 511830, 511829, 379418, Fax. (0274) 564604

SURAT TUGAS

Nomor : F10/036/B.12/II/2022

Yang bertanda tangan di bawah ini Pimpinan Fakultas Kesehatan Masyarakat Universitas Ahmad Dahlan, dengan ini menugaskan kepada:

Nama : Solikhah S.KM., M.Kes., Dr.PH
NIP/NIY : 60050527
Jabatan : Dosen Prodi S2 Kesehatan Masyarakat

Untuk : Menjadi *reviewer* Jurnal Internasional Bereputasi

No.	Nama Jurnal	Judul Artikel	Penerbit
1	<i>Breast Cancer: Targets and Therapy</i> SJR: 0,808	<i>Effect of Xihuang Pill's Regulation of Ferroptosis Related Genes on the Prognosis of Breast Cancer Patients</i>	Dove Medical Press

Demikian surat tugas ini dibuat kepada yang bersangkutan untuk dilaksanakan dengan penuh rasa tanggung jawab, dan melaporkan kepada pimpinan setelah selesai melaksanakan tugas.

Yogyakarta, 2 Jumadal Akhirah 1443 H
3 Februari 2022 M



Dekan
Lina Handayani, S.KM., M.Kes., Ph.D
NIY. 60030447

Tembusan:
Kaprosdi Magister Kesmas

Dove Medical Press invites you to review a paper for Breast Cancer: Targets and Therapy Submission ID: 355923

1 message

Mr Ash Oldham <ashleyoldham@dovepress.com>
Reply-To: Mr Ash Oldham <ashleyoldham@dovepress.com>
To: solikhah@ikm.uad.ac.id

Thu, Feb 3, 2022 at 9:43 PM

Dear Dr Solikhah

Dove Medical Press invites you to join our peer review community. Our expert reviewers greatly contribute to the high standards of the journal.

The reviewer selection team search and invite peer reviewers in the same area of medicine and science as our authors and we hope that you will be willing to provide your expert assessment on this article.

Manuscript title: Effect of Xihuang Pill's Regulation of Ferroptosis Related Genes on the Prognosis of Breast Cancer Patients

Article type: Original Research

Author: Dr Xu-kuo Liu

Journal: Breast Cancer: Targets and Therapy
<https://www.dovepress.com/breast-cancer---targets-and-therapy-journal>

Abstract: Objective: Explore the effects of Ferroptosis-related genes regulated by Xihuang Pill on the prognosis of breast cancer patients. Method: Use the HERB Database and ferroptosis database (FerrDb) to retrieve the ferroptosis-related genes regulated by Xihuang Pill. Use the TCGA database to extract the expression levels of ferroptosis-related genes regulated by Xihuang Pill of breast cancer patients. Single-factor Cox regression analysis was used to find the ferroptosis genes related to the prognosis, and cross the differential genes to obtain the differential ferroptosis genes related to the prognosis. LASSO Cox regression analysis was used to construct a prognostic model. According to the median value of the model's risk score, patients were divided into high-risk groups and low-risk groups. The Kaplan-Meier survival curve and ROC curve were used to evaluate the predictive ability of the prognostic model. And use GO enrichment analysis, KEGG pathway analysis, and ssGSEA immun assay to analyze the biological functions and mechanisms of risk score-related genes. Result: Xihuang Pill has 1351 targets and 54 ferroptosis-related genes. Among them, 46 ferroptosis-related genes were differentially expressed between breast cancer and adjacent normal tissues, and 8 ferroptosis-related genes were differentially expressed with prognostic survival ($p < 0.05$). Compared with the low-risk group, the overall survival rate of the high-risk group was significantly lower ($p < 0.001$). In the multivariate Cox regression analysis, the risk score can be used as an independent prognostic factor ($p < 0.001$). The Kaplan-Meier survival curve and ROC curve show that the accuracy of predicting patient survival through this model is relatively high. The GO, KEGG, and ssGSEA analysis of risk score-related genes found that they were related to immunity ($p < 0.001$). Conclusion: The eight ferroptosis-related genes regulated by Xihuang Pill can be used to predict the prognosis of breast cancer, which may be the mechanism of the Xihuang Pill to improve the prognosis of patients.

We would appreciate your response to this email by 11 Feb 2022. If you agree to review this manuscript, your comments will be due 10 days from accepting the invitation.

Peer-review comments can only be accepted online via our reviewer system. We cannot accept downloaded manuscript files that you have annotated or modified in any way.

This link https://www.dovepress.com/reviews.php?!=GqQCyVvYWF4LDGIoR2jyRsH1148624&review_id=4339862 will take you directly to your peer review interface (a password isn't required). You will be able to:

- Accept or decline the review invitation
- We provide a structured peer review evaluation form which guides the reviewer through the important points for consideration when evaluating a manuscript.
- Information on Peer Review guidelines
- Download all files

The authors manuscript or existence of a manuscript is provided to you on a confidential basis. An author's manuscript may not be disclosed in whole, or in part, to any third party under any circumstances. In addition, you may not forward this invitation to any third party. It is a personal invitation to you alone.

I thank you for considering our invitation.

If you have any questions do not hesitate to contact me.

Yours sincerely

Mr Ash Oldham
On behalf of Professor Pranela Rameshwar
Breast Cancer: Targets and Therapy
Dove Medical Press
www.dovepress.com - open access to scientific and medical research

If you do not wish to receive further invitations to review Dove Press papers, please click here:
https://www.dovepress.com/disable_peer_review.php?fp=dose367&u=solikhah

Peer Review for Breast Cancer: Targets and Therapy [ID: 355923]

1 message

Mr Oldham <ashleyoldham@dovepress.com>
Reply-To: Mr Oldham <ashleyoldham@dovepress.com>
To: Dr Solikhah <solikhah@ikm.uad.ac.id>

Thu, Feb 17, 2022 at 2:39 PM

Dear Dr Solikhah

This is to confirm we have received your peer review comments for:

Title: Effect of Xihuang Pill's Regulation of Ferroptosis Related Genes on the Prognosis of Breast Cancer Patients

The time and effort that you have put into this review is most appreciated. You will be sent a peer review acknowledgement certificate once the editorial team have processed your review.

If I can be of further assistance, please do not hesitate to contact me.

Kind regards

Mr Oldham
[ID: 355923]

Peer Review for Breast Cancer: Targets and Therapy [ID: 355923]

1 message

Mr Oldham <ashleyoldham@dovepress.com>
Reply-To: Mr Oldham <ashleyoldham@dovepress.com>
To: Dr Solikhah <solikhah@ikm.uad.ac.id>

Thu, Feb 17, 2022 at 2:39 PM

Dear Dr Solikhah

This is to confirm we have received your peer review comments for:
Title: Effect of Xihuang Pill's Regulation of Ferroptosis Related Genes on the Prognosis of Breast Cancer Patients

The time and effort that you have put into this review is most appreciated. You will be sent a peer review acknowledgement certificate once the editorial team have processed your review.

If I can be of further assistance, please do not hesitate to contact me.

Kind regards
Mr Oldham
[ID: 355923]

Thank you for the review

1 message

Jenny Dalton <jennydalton@dovepress.com>
Reply-To: Jenny Dalton <jennydalton@dovepress.com>
To: solikhah@ikm.uad.ac.id

Fri, Feb 18, 2022 at 3:22 AM

Dr Solikhah

Journal Name: Breast Cancer: Targets and Therapy
Title: Effect of Xihuang Pill's Regulation of Ferroptosis Related Genes on the Prognosis of Breast Cancer Patients
Submission ID: 355923

On behalf of the author(s) and Dove Medical Press I would like to thank you for providing peer review comments for this manuscript. The time and effort that you have put into this review is most appreciated.

You can now view and download your peer-reviewer acknowledgement certificate here (just click on "Breast Cancer: Targets and Therapy" to view the PDF):
https://www.dovepress.com/peer_reviewer_acknowledgement.php?l=GqQCvVvYWF4LDGIoR2jyRsH1148624

To see your current and previous reviewed contributions, you can also go to our reviewer summary page in your account; <https://www.dovepress.com/reviews.php?pa=history&l=GqQCvVvYWF4LDGIoR2jyRsH1148624>

As one of our peer-reviewers you will receive a written acknowledgement for your efforts. In addition, each journal will publish an annual list of peer-reviewers that have contributed to the journal.

I would also like to take this opportunity to invite you to submit a manuscript to one of our journals through our Favored Author Program. This will give you the following benefits on any papers you submit to us:

- * 10% discount on your publication processing fee.
- * Fast-track processing of papers.
- * Rapid delivery of a PDF of your paper for your personal use.

To join this program simply register here https://www.dovepress.com/fav_author.php
Alternatively you can reply to this email. I will be in contact to make arrangements.

These benefits start from the time you join our Favored Author program and will apply to all papers you submit after this point.
Favored Author must be submitting author and use registered email address to receive discount. Discount cannot be applied retrospectively to already submitted papers.

Regards

Jenny Dalton
Dove Medical Press
www.dovepress.com - open access to scientific and medical research
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

Manuscript ID number: 355923

Title of paper: Effect of Xihuang Pill's Regulation of Ferroptosis-Related Genes on Prognosis of Patients with Breast Cancer

Reviewed by: Dr Solikhah on 10 March 2023

Title & Abstract

1. Do the title and abstract cover the main aspect of the work?

Yes, this manuscript has a novelty; however, the method section need to explain more for identifying cases and design sampling, inclusion and exclusion criteria.

Introduction

2. Does the introduction provide background and information relevant to the study?

Yes

Material and Methods

3. Are the methods clear and replicable? Do all the results presented match the methods described?

The method needs to explain more how to get this sample and what are the inclusion and exclusion of this sample. This section also identifies how to measure all variables regarding the statistical analysis. Importantly, identifying cases is not clear, how to measure and what kind of tool for measuring these cases. Have any confounding factors in this study?

Results

4. If relevant are the results novel? Does the study provide an advance in the field? Is the data plausible?

Yes

Discussion

5. Do the findings described by the author correlate with the results? Are the findings relevant?

Yes

Conclusion

6. Do the conclusions correlate to the results found?

Yes

Figures & Tables

7. If the author has provided figures and tables are the figures and tables clear and legible? Are the figures free from unnecessary modification?

Yes

8. Does the paper raise any concerns?

No.

Competing interest

9. Do any of the authors' competing interests raise concerns about the validity of the study i.e. have the authors' competing interests created a bias in the reporting of the results and conclusions?

None

Recommendations to the Editor

10. Recommendations to Editors

Fair

11. Would you be willing to review a revision of this manuscript?

No

Additional comments

This manuscript has a novelty and good flow written. However, the method needs to explain more how to get this sample and what are the inclusion and exclusion of this sample. This section also identifies how to measure all variables regarding the statistical analysis. Importantly, identifying cases is not clear, how to measure and what kind of tool for measuring these cases. Have any confounding factors in this study?

Confidential comments for Editor

-

Competing Interest Disclosure

none

Peer Reviewer Competing Interest Disclosure

-

To whom it may concern

Dr Solikhah Solikhah has reviewed 1 submission in the journal *Breast Cancer: Targets and Therapy* (journal Impact Factor: 5.088) during 2022.

This contribution is greatly appreciated.

Regards

Angela Jones

General Manager, Dove Medical Press Ltd

Dove Medical Press (NZ) Ltd, 44 Corinthian Drive, Albany, Auckland, New Zealand

PO Box 300-008, Albany, Auckland, 0752, New Zealand

p +649 443 3060 **f** +649 443 3061 **e** info@dovepress.com

Live Chat https://www.dovepress.com/live_help.t

Twitter <https://twitter.com/DovePress>

www.dovepress.com - open access to scientific and medical research